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The decades-old debate about the optimum
organizational structure of the National
Institute on Alcohol Abuse and Alcoholism
(NIAAA) and National Institute on Drug
Abuse (NIDA) has reached a crescendo with
the recent deliberations of the Scientific
Management Review Board, which, despite
the lack of a crisis, proposed a structural
reorganization that would dissolve the two
institutes and create a new institute for substance use, abuse, and addiction, in hope of
new scientific and public health advances
(Collins, 2010). For a new institute to succeed, a multitude of potential challenges
need to be negotiated effectively.
Notably, new funds will be needed, even
in the current difficult national economic
climate, to coalesce the infrastructure of
NIAAA and NIDA and incorporate addiction-related research currently conducted
by other National Institutes of Health (NIH)
institutes. To succeed, the new institute
would also require an enormous amount
of cooperation from other institutes as the
portfolios of research in the areas of alcohol,
tobacco, and other drug abuse are transferred
to it. Thus, in the near term, a structural reorganization would be less efficient and more
costly than the individual institutes are currently. Only with careful strategic planning
would it be possible to increase efficiency and
reduce costs over time.
If the process moves forward smoothly,
Dr. Francis Collins, NIH Director, has proposed launching the new entity by October
2012. However, if reorganization is to be
unveiled slowly and progressively over the
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next 2 years with gradual integration of two
disparate cultures, another approach could
be to intensify and strengthen current collaborations through an NIAAA–NIDA
Joint Task Force. The NIH Director could
determine a specific percentage of resources
from each institute to be committed for
collaborative research agendas modeled on
the same governance and operational structures currently used by the Neuroscience
Blueprint and the Basic Behavioral Research
Operations Network. In this way, a clearer
road map could be developed that provides
for due diligence and critical information
gathering to understand the practical needs
and challenges of developing an informed
organizational approach. Predetermined
milestones can be used to evaluate progress
and adjust course as needed to ensure a viable
plan that incorporates all relevant research.
Importantly, although there are common mechanisms mediating the rewarding effects of alcohol and other drugs,
distinctions also exist. For example, there
is considerable evidence that substances of
abuse express their addictive potential, in
part, through similar brain circuits, most
notably the cortico-mesolimbic dopamine
circuit (Johnson, 2010). Nevertheless,
despite decades of research, the approach
of direct antagonism of cortico-mesolimbic dopamine receptors has not yet yielded
efficacious medicines to treat addiction. In
fact, pharmacological differences between
alcohol and other drugs might hold the key
to successful medications development for
these different disorders. Thus, rather than

focusing on a narrow conceptualization of
the addiction circuitry, the new institute
should seek diligently to understand how
diverse and complex mechanisms contribute to abuse of alcohol and other substances.
Nutt et al. (2010) noted that in the
United Kingdom, the overall harm to both
the individual and others was greatest for
alcohol. Alcohol is the addictive substance
that is most commonly used by the United
States population, with a prevalence of
about 65.4% (Table 1; Grant et al., 2011).
Addiction to alcohol is, however, far less
common, as a proportion of its use, than
addiction to many other drugs of abuse.
Nonetheless, Rehm et al. (2009) found that
the total economic cost of alcohol abuse in
the United States in 1998 was nearly $235
billion (adjusted to 2007 international dollars). The harm to society attributed to alcohol consumption often results from alcohol
use disorders that include the inappropriate
use of alcohol in situations such as before
driving or by underage drinkers, rather
than addiction to alcohol. A 2010 fact sheet
from the Centers for Disease Control and
Prevention reports that during 2000–2004,
annual health-related economic losses in
the United States due to cigarette smoking
were estimated at $193 billion ($96 billion
in direct medical costs plus $97 billion in
lost productivity). Data from the Office
of National Drug Control Policy in 2002
showed that the total economic impact in
the United States of all illicit drugs combined was about $200 billion, but 60% of
that amount was related to incarceration.
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Table 1 | Past-year liability for various types of substance dependence, based on 200 million United States adults ≥18 years of age (2001–2002).
Prevalence (%)

Number of individuals

Percentage of past-year

Number of individuals

of past-year use

with past-year use

users with past-year dependence

with past-year dependence

Alcohol

65.44

130,880,000

5.82

7,617,216

Tobacco

27.66

55,320,000

46.13

25,519,116
134,416

Sedatives

1.24

2,480,000

5.42

Tranquilizers

0.93

1,860,000

5.04

93,744

Painkillers

1.81

3,620,000

6.3

228,060

Stimulants

0.49

980,000

14.34

140,532

Marijuana

4.07

8,140,000

7.96

647,944

Cocaine/crack

0.56

1,120,000

23.91

267,792

Hallucinogens

0.57

1,140,000

2.67

30,438

Solvents/inhalants

0.11

220,000

1.04

2,288

Heroin

0.03

60,000

26.96

16,176

The data in this table are from Wave I of the National Epidemiologic Survey on Alcohol and Related Conditions (2001–2002; Grant et al., 2011).

Hence, the new institute should focus on (1)
alcohol use disorders, including alcoholism,
(2) tobacco addiction, and (3) illicit drug
addictions as a group, in that order.
Careful thought is needed to determine
the programmatic components of the new
institute. Fragmentation or segregation of
ongoing programs such as those involving
fetal alcohol spectrum disorders, alcoholic
liver disease, or prevention and treatment
does not serve the public good and must
be avoided. Tobacco research should be
a major focus of a new institute and not
the sole purview of the National Cancer
Institute (NCI) or National Heart, Lung
and Blood Institute (NHLBI) so that the
prevention and treatment of tobacco
addiction is not subsumed by the study of
its general health consequences. Indeed,
tobacco is, by far, the most addictive of
all the drugs (Table 1), followed by heroin
and crack cocaine (percentage of pastyear users with past-year dependence;
Grant et al., 2011). It would certainly be
unreasonable to expect scientists within
NCI and NHLBI to be experts on addiction, and for many, such specialist training
would be lacking. Comorbid alcohol and
drug addiction is at the interface of a collaborative scientific enterprise and, in the
future, should receive appropriate funding and opportunities for development.
Because of the strong interrelationship
between alcohol and tobacco use, abuse,
and addiction, a new institute would not
be well grounded if it did not incorporate
both. It is intriguing to consider whether
parts of the National Institute of Mental
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Health should also be included within
this new institute to address prevention
and treatment of comorbid substance use
disorder and mental illness, as well as some
behavioral addictive disorders.
These deliberations have identified an
opportunity to increase collaboration and
broaden the thinking and vision of scientists
to promote public health. If a new institute
for substance use, abuse, and addiction is
established, new leadership that is credible
and respected by both the alcohol and drug
addiction communities is needed to drive
the new institute, inspire new vistas, build
more intensive collaborations, and motivate
staff to do what they have always done best
– serve the public good. Otherwise, the path
toward a structural reorganization of a new
institute that meets some of the promise
proposed for it, even with careful and strategic planning, could become a famished
road (Okri, 1992) that simply consumes
people and resources with no tangible gains.
Success in this difficult task would be made
easier and less costly by first implementing
carefully placed building blocks of increasing functional reorganization. Indeed, for
the structural reorganization of a new institute to succeed, attention needs to be paid
to the devil in the details.
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